Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a U.S. patent for a proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Group 1: Patent and Technology - The newly granted U.S. patent complements existing patents in the U.S. and Europe, reinforcing global intellectual property protection for NeuroThera's antimicrobial-potentiating platform [2]. - The patented technology combines established antibiotics with cannabinoids like Δ⁹-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), showing enhanced antimicrobial activity in pre-clinical studies against resistant Gram-positive pathogens such as MRSA [3][5]. - The platform aims to leverage the long-term safety data of these antibiotics to minimize risks while providing an effective and affordable therapeutic solution [3]. Group 2: Market Context and Need - Prolonged antibiotic use has led to the emergence of resistant bacterial strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, a significant increase from 57,000 deaths in 2019 [4]. - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The "antimicrobial-sparing" effect of NeuroThera's combination may reduce the need for new antibiotics, addressing serious side effects associated with resistance development and organ toxicity [7]. Group 3: Industry Challenges - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to long development timelines, high costs, and rapid bacterial resistance, leading to a decline in innovation in this field [8].

Core Viewpoint - Neurothera Labs Inc. has received a U.S. patent for its proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Company Summary - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics, particularly in the area of antimicrobial resistance [10]. - The company is a majority-owned subsidiary of SciSparc Ltd. [1]. Technology and Innovation - The patented technology combines established antibiotics with cannabinoids like THC and CBD, demonstrating enhanced antimicrobial activity against resistant pathogens such as MRSA in preclinical studies [3][5]. - The platform aims to restore the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens [3]. Market Context - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The emergence of resistant bacterial strains, particularly MRSA, has led to a significant increase in healthcare-acquired infections, with a reported 30% rise in the U.S. [6]. Antimicrobial Resistance Challenge - Prolonged antibiotic use has resulted in the emergence of resistant strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, more than double the 57,000 deaths in 2019 [4]. - Overall, bacterial antimicrobial resistance caused 1.14 million deaths and was associated with 4.71 million deaths globally in 2021 [4]. Industry Dynamics - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to high costs and lengthy development timelines, leading to a gap in innovation as major firms exit the field [8][9]. - The need for innovative solutions that enhance the efficacy of existing antibiotics while improving safety is critical in the current landscape of antimicrobial resistance [6][7].

Core Insights - SciSparc Ltd. has acquired an IP portfolio from Xylo Technologies, including the MUSE™ system, targeting the global multi-billion dollar GERD device market [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately and aims for rapid market penetration and revenue generation [2] Market Opportunity - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a CAGR of 3.24% from 2025 to 2030 [5] - SciSparc intends to replicate Xylo's successful commercialization model from Greater China in high-growth regions like North America, Europe, and Latin America [3] Acquisition Details - SciSparc acquired the complete portfolio of patents and related intellectual property rights associated with the MUSE™ system, issuing shares that represent 19.99% of its outstanding share capital to Xylo [4]

Core Viewpoint - SciSparc Ltd. announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand its presence in the medical device sector and accelerate commercialization plans [1][2][3]. Group 1: Acquisition Details - The acquisition includes patents, trademarks, and related rights associated with endoscopic systems and medical cameras, specifically the MUSE endoscopic system designed for minimally invasive procedures [2]. - The company plans to issue ordinary shares to the seller at closing, which will represent approximately 19.99% of the company's outstanding stock [4]. - SciSparc may opt to issue pre-funded warrants instead of some shares at its discretion [5]. Group 2: Commercial Strategy - SciSparc intends to commercialize the acquired technologies immediately after the deal closes, aiming to replicate existing successful distribution models [4]. - The company plans to leverage licensing and regional partnerships to expand its market reach in North America, Europe, and Latin America [4]. Group 3: Closing Conditions and Market Outlook - The acquisition is subject to customary conditions, including regulatory approvals, with an expected closing date by March 8, 2026 [6]. - A market research report indicates growth in the global GERD device market, driven by demand for innovative endoscopy systems, which may help SciSparc extend its reach into new medical segments alongside its pharmaceutical initiatives [6]. Group 4: Stock Performance - Following the announcement, SciSparc shares were trading lower by 12.07% to $1.27 [7].

SciSparc Ltd. (SPRC), Tuesday announced a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE system, from Xylo Technologies Ltd. The company will issue an amount of its common shares to Xylo in consideration for the acquired assets.Upon closing of the deal, SciSparc intends to commence commercialization of these patented technologies immediately, which is expected to boost rapid market ...

SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopi ...

Core Viewpoint - SciSparc Ltd. has received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement for continued listing, reporting stockholders' equity of approximately $(81,000) as of June 30, 2025, against a required minimum of $2,500,000 [1][2] Group 1: Compliance and Financial Status - The company has 45 calendar days to submit a plan to regain compliance, with a deadline of February 26, 2026, and may receive an extension of up to 180 days if the plan is accepted [2] - The company expects to demonstrate compliance with Nasdaq's stockholders' equity requirement as of December 31, 2025, following proceeds from a conversion of $4.2 million in principal and accrued interest from debentures and a registered direct offering in November 2025 [3] Group 2: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., with a portfolio centered on cannabinoid pharmaceuticals [4] - Current drug development programs include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism spectrum disorder and status epilepticus [4]

Core Points - Neurothera Labs Inc. held its annual and special meeting of shareholders on January 8, 2026, where key decisions were made regarding the company's governance and future plans [1] Group 1: Shareholder Decisions - All nominee directors listed in the management information circular dated December 4, 2025, were elected as directors [2] - Shareholders voted to appoint Dale Matheson Carr-Hilton Labonte LLP as auditors for the upcoming year and authorized the directors to fix their remuneration [2] - A consolidation of common shares was authorized, allowing for a potential consolidation of one post-consolidation share for up to one hundred pre-consolidation shares, subject to the directors' discretion and market conditions [3] - The adoption of a 20% fixed equity incentive plan was approved, pending final approval from the TSX Venture Exchange [4] Group 2: Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [5]

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a patent in Israel for a proprietary combination of opioids and N-acylethanolamines, aimed at enhancing opioid efficacy while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening NeuroThera's global intellectual property protection [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance the analgesic effects of opioids like oxycodone, allowing for effective pain relief at lower doses [3][5]. - Pre-clinical studies demonstrated that the combination of oxycodone and PEA not only improved pain relief but also reduced adverse psychoactive effects associated with oxycodone [5]. Group 2: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant demand for opioid medications [6]. - The opioid-sparing effect of NeuroThera's combination may lead to lower required dosages of opioids, potentially mitigating risks such as addiction and respiratory depression [7]. Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its subsidiary NeuroThera Labs Inc., which is engaged in creating novel therapeutics for central nervous system disorders [9][10]. - The company is also involved in developing cannabinoid-based pharmaceuticals, with ongoing programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [9].

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].